Activated, HTLV-1-specific cytotoxic T-lymphocytes are found in healthy seropositives as well as in patients with tropical spastic paraparesis
- PMID: 1374983
- DOI: 10.1016/0042-6822(92)90517-s
Activated, HTLV-1-specific cytotoxic T-lymphocytes are found in healthy seropositives as well as in patients with tropical spastic paraparesis
Abstract
In human T cell lymphoma/leukemia virus (HTLV-1)-infected people with tropical spastic paraparesis (TSP), there are activated HTLV-1-specific cytotoxic T lymphocytes (CTL) in the circulation and lymphocytic infiltrates in spinal cord lesions that are rich in CD8+ T cells. These observations suggest a role for virus-specific CTL in the pathogenesis of TSP. We have examined the anti-HTLV-1 cytotoxic activity of freshly isolated CD8+ T cells from peripheral blood lymphocytes of eight subjects seropositive for HTLV-1. Four of five subjects with TSP had circulating activated anti-Tax CTL. However, two of three seropositive subjects without TSP also had activated anti-Tax CTL. These observations show that such activated CTL are not confined to patients with TSP and raise some uncertainty about their significance in the pathogenesis of the disease. In cultures of CD8+ T cells from two TSP subjects, we detected CTL with other HTLV-1 specificities, without exogenous antigenic stimulation. A CTL epitope in the middle region of Tax and one in the C terminus of Pol have been mapped at the peptide level and the HLA Class 1 molecules restricting their recognition have been defined.
Similar articles
-
Short communication an interferon-γ ELISPOT assay with two cytotoxic T cell epitopes derived from HTLV-1 tax region 161-233 discriminates HTLV-1-associated myelopathy/tropical spastic paraparesis patients from asymptomatic HTLV-1 carriers in a Peruvian population.AIDS Res Hum Retroviruses. 2011 Nov;27(11):1207-12. doi: 10.1089/AID.2011.0029. Epub 2011 May 9. AIDS Res Hum Retroviruses. 2011. PMID: 21453202
-
High activated and memory cytotoxic T-cell responses to HTLV-1 in healthy carriers and patients with tropical spastic paraparesis.Virology. 1996 Mar 1;217(1):139-46. doi: 10.1006/viro.1996.0101. Virology. 1996. PMID: 8599198
-
Predominant recognition of human T cell leukemia virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic T cells directed against HTLV-I-infected cells.Int Immunol. 1991 Aug;3(8):761-7. doi: 10.1093/intimm/3.8.761. Int Immunol. 1991. PMID: 1911545
-
Virological aspects of tropical spastic paraparesis/HTLV-I associated myelopathy and HTLV-I infection.J Neurovirol. 1996 Oct;2(5):299-306. doi: 10.3109/13550289609146894. J Neurovirol. 1996. PMID: 8912206 Review.
-
HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP): the role of HTLV-I-infected Th1 cells in the pathogenesis, and therapeutic strategy.Folia Neuropathol. 2009;47(2):182-94. Folia Neuropathol. 2009. PMID: 19618340 Review.
Cited by
-
Evidence for the chronic in vivo production of human T cell leukemia virus type I Rof and Tof proteins from cytotoxic T lymphocytes directed against viral peptides.J Exp Med. 2000 Feb 7;191(3):567-72. doi: 10.1084/jem.191.3.567. J Exp Med. 2000. PMID: 10662802 Free PMC article.
-
Tax-independent constitutive IkappaB kinase activation in adult T-cell leukemia cells.Neoplasia. 2004 May-Jun;6(3):266-78. doi: 10.1593/neo.3388. Neoplasia. 2004. PMID: 15153339 Free PMC article.
-
Among all human T-cell leukemia virus type 1 proteins, tax, polymerase, and envelope proteins are predicted as preferential targets for the HLA-A2-restricted cytotoxic T-cell response.J Virol. 1996 Aug;70(8):4919-26. doi: 10.1128/JVI.70.8.4919-4926.1996. J Virol. 1996. PMID: 8763995 Free PMC article.
-
The transcriptome of HTLV-1-infected primary cells following reactivation reveals changes to host gene expression central to the proviral life cycle.PLoS Pathog. 2023 Jul 31;19(7):e1011494. doi: 10.1371/journal.ppat.1011494. eCollection 2023 Jul. PLoS Pathog. 2023. PMID: 37523412 Free PMC article.
-
Human T-cell leukemia virus type 1 (HTLV-1) p12I down-modulates ICAM-1 and -2 and reduces adherence of natural killer cells, thereby protecting HTLV-1-infected primary CD4+ T cells from autologous natural killer cell-mediated cytotoxicity despite the reduction of major histocompatibility complex class I molecules on infected cells.J Virol. 2007 Sep;81(18):9707-17. doi: 10.1128/JVI.00887-07. Epub 2007 Jul 3. J Virol. 2007. PMID: 17609265 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous